Biotron Ltd (BIT) - Net Assets

Latest as of June 2026: AU$2.92 Million AUD ≈ $2.07 Million USD

Based on the latest financial reports, Biotron Ltd (BIT) has net assets worth AU$2.92 Million AUD (≈ $2.07 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$3.74 Million ≈ $2.65 Million USD) and total liabilities (AU$817.93K ≈ $578.74K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check strategic asset allocation of Biotron Ltd to assess the company's strategic physical and investment asset allocation.

Key Net Assets Metrics

Metric Value
Current Net Assets AU$2.92 Million
% of Total Assets 78.12%
Annual Growth Rate -9.76%
5-Year Change 167.37%
10-Year Change 102.83%
Growth Volatility 135.68

Biotron Ltd - Net Assets Trend (2000–2026)

This chart illustrates how Biotron Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Biotron Ltd market cap and net worth.

Annual Net Assets for Biotron Ltd (2000–2026)

The table below shows the annual net assets of Biotron Ltd from 2000 to 2026. Also explore BIT net assets growth trend to track the company's year-over-year net asset growth rate.

Year Net Assets Change
2026-06-30 AU$2.92 Million
≈ $2.07 Million		 +429.26%
2025-06-30 AU$551.89K
≈ $390.50K		 +326.16%
2024-06-30 AU$-244.03K
≈ $-172.67K		 -107.69%
2023-06-30 AU$3.17 Million
≈ $2.24 Million		 +190.40%
2022-06-30 AU$1.09 Million
≈ $773.01K		 -71.72%
2021-06-30 AU$3.86 Million
≈ $2.73 Million		 -44.60%
2020-06-30 AU$6.97 Million
≈ $4.93 Million		 +28.20%
2019-06-30 AU$5.44 Million
≈ $3.85 Million		 +324.42%
2018-06-30 AU$1.28 Million
≈ $906.75K		 -11.01%
2017-06-30 AU$1.44 Million
≈ $1.02 Million		 -54.09%
2016-06-30 AU$3.14 Million
≈ $2.22 Million		 -24.28%
2015-06-30 AU$4.14 Million
≈ $2.93 Million		 +198.21%
2014-06-30 AU$1.39 Million
≈ $983.02K		 -68.96%
2013-06-30 AU$4.48 Million
≈ $3.17 Million		 -45.88%
2012-06-30 AU$8.27 Million
≈ $5.85 Million		 +244.52%
2011-06-30 AU$2.40 Million
≈ $1.70 Million		 +39.75%
2010-06-30 AU$1.72 Million
≈ $1.22 Million		 +104.11%
2009-06-30 AU$841.51K
≈ $595.42K		 -54.35%
2008-06-30 AU$1.84 Million
≈ $1.30 Million		 +35.94%
2007-06-30 AU$1.36 Million
≈ $959.47K		 -69.84%
2006-06-30 AU$4.50 Million
≈ $3.18 Million		 +97.30%
2005-06-30 AU$2.28 Million
≈ $1.61 Million		 -22.91%
2004-06-30 AU$2.96 Million
≈ $2.09 Million		 -48.69%
2003-06-30 AU$5.76 Million
≈ $4.08 Million		 -32.14%
2002-06-30 AU$8.49 Million
≈ $6.01 Million		 -15.78%
2001-06-30 AU$10.08 Million
≈ $7.13 Million		 -76.11%
2000-06-30 AU$42.20 Million
≈ $29.86 Million		 --

Equity Component Analysis

This analysis shows how different components contribute to Biotron Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 6014913500.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (June 2026)

Component Amount Percentage
Common Stock AU$62.60 Million 2142.94%
Other Comprehensive Income AU$617.06K 21.12%
Total Equity AU$2.92 Million 100.00%

Biotron Ltd Competitors by Market Cap

The table below lists competitors of Biotron Ltd ranked by their market capitalization.

Company Market Cap
Soco Corporation Ltd
AU:SOC
 $3.94 Million
TAIZHOU WATER GRP. H YC 1
F:GX5
 $3.95 Million
Kane Biotech Inc
V:KNE
 $3.95 Million
Euroespes S.A.
MC:EEP
 $3.95 Million
DOREL INDS INC. A
F:DO4C
 $3.94 Million
International Lithium Corp
V:ILC
 $3.94 Million
Inix Technologies Holdings Bhd
KLSE:0094
 $3.94 Million
Autonomix Medical, Inc. Common Stock
NASDAQ:AMIX
 $3.93 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Biotron Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2025 to 2026, total equity changed from 551,895 to 2,920,986, a change of 2,369,091 (429.3%).
  • Net loss of 1,518,303 reduced equity.
  • Other comprehensive income increased equity by 617,056.
  • Other factors increased equity by 3,270,338.

Equity Change Factors (2025 to 2026)

Factor Impact Contribution
Net Income AU$-1.52 Million -51.98%
Other Comprehensive Income AU$617.06K +21.12%
Other Changes AU$3.27 Million +111.96%
Total Change AU$- 429.26%

Book Value vs Market Value Analysis

This analysis compares Biotron Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.42x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has increased from 0.00x to 1.42x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2000-06-30 AU$0.57 AU$0.00 x
2001-06-30 AU$0.15 AU$0.00 x
2002-06-30 AU$0.10 AU$0.00 x
2003-06-30 AU$0.07 AU$0.00 x
2004-06-30 AU$0.03 AU$0.00 x
2005-06-30 AU$0.03 AU$0.00 x
2006-06-30 AU$0.05 AU$0.00 x
2007-06-30 AU$0.01 AU$0.00 x
2008-06-30 AU$0.02 AU$0.00 x
2009-06-30 AU$0.01 AU$0.00 x
2010-06-30 AU$0.01 AU$0.00 x
2011-06-30 AU$0.01 AU$0.00 x
2012-06-30 AU$0.03 AU$0.00 x
2013-06-30 AU$0.02 AU$0.00 x
2014-06-30 AU$0.00 AU$0.00 x
2015-06-30 AU$0.01 AU$0.00 x
2016-06-30 AU$0.01 AU$0.00 x
2017-06-30 AU$0.00 AU$0.00 x
2018-06-30 AU$0.00 AU$0.00 x
2019-06-30 AU$0.01 AU$0.00 x
2020-06-30 AU$0.01 AU$0.00 x
2021-06-30 AU$0.01 AU$0.00 x
2022-06-30 AU$0.00 AU$0.00 x
2023-06-30 AU$0.00 AU$0.00 x
2024-06-30 AU$0.00 AU$0.00 x
2025-06-30 AU$0.00 AU$0.00 x
2026-06-30 AU$0.00 AU$0.00 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Biotron Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -51.98%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 0.00%
  • • Asset Turnover: 0.00x
  • • Equity Multiplier: 1.28x
  • Recent ROE (-51.98%) is above the historical average (-97.08%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2001 -12.70% -9800.92% 0.00x 1.01x AU$-2.29 Million
2002 -19.64% -2657.00% 0.01x 1.02x AU$-2.52 Million
2003 -47.36% -912.61% 0.05x 1.03x AU$-3.30 Million
2005 -82.66% -1416.22% 0.05x 1.07x AU$-2.11 Million
2006 -48.91% -276.65% 0.17x 1.07x AU$-2.65 Million
2007 -238.49% -803.57% 0.26x 1.12x AU$-3.37 Million
2008 -102.10% 0.00% 0.00x 1.23x AU$-2.07 Million
2009 -211.06% 0.00% 0.00x 1.26x AU$-1.86 Million
2010 -109.01% 0.00% 0.00x 1.08x AU$-2.04 Million
2011 -79.47% 0.00% 0.00x 1.10x AU$-2.15 Million
2012 -28.76% 0.00% 0.00x 1.02x AU$-3.21 Million
2013 -86.05% -431.72% 0.18x 1.09x AU$-4.30 Million
2014 -222.11% -179.15% 0.92x 1.34x AU$-3.22 Million
2015 -65.73% -162.85% 0.36x 1.11x AU$-3.14 Million
2016 -95.77% -194.05% 0.44x 1.11x AU$-3.32 Million
2017 -214.80% -186.41% 0.81x 1.43x AU$-3.24 Million
2018 -124.36% -98.22% 1.00x 1.26x AU$-1.72 Million
2019 -29.63% -150.24% 0.18x 1.08x AU$-2.16 Million
2020 -51.28% -445.31% 0.10x 1.12x AU$-4.27 Million
2021 -82.69% -218.50% 0.34x 1.12x AU$-3.58 Million
2022 -254.56% -178.44% 0.82x 1.74x AU$-2.89 Million
2023 -110.09% -244.03% 0.35x 1.30x AU$-3.81 Million
2024 0.00% -208.89% 3.33x 0.00x AU$-3.41 Million
2025 -57.72% -17.57% 1.85x 1.78x AU$-373.76K
2026 -51.98% 0.00% 0.00x 1.28x AU$-1.81 Million

Industry Comparison

This section compares Biotron Ltd's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $21,529,712
  • Average return on equity (ROE) among peers: -74.59%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Biotron Ltd (BIT) AU$2.92 Million -12.70% 0.28x $3.94 Million
Adalta Ltd (1AD) $7.75 Million -36.57% 0.04x $6.31 Million
Algorae Pharmaceuticals Ltd (1AI) $7.52 Million -54.40% 0.16x $14.31 Million
ACRUX Ltd (ACR) $29.97 Million -47.32% 0.08x $2.61 Million
Actinogen Medical Ltd (ACW) $24.00K 0.00% 1.21x $130.32 Million
Argenica Therapeutics Ltd (AGN) $7.67 Million -62.81% 0.24x $13.63 Million
Arovella Therapeutics Ltd (ALA) $11.03 Million -40.87% 0.23x $49.61 Million
Anatara Lifesciences Ltd (ANR) $535.97K -364.70% 1.14x $1.57 Million
Alterity Therapeutics Ltd (ATH) $5.62 Million -93.17% 0.31x $108.75 Million
Amplia Therapeutics Ltd (ATX) $11.42 Million -39.44% 0.30x $45.40 Million
Avecho Biotechnology Ltd (AVE) $133.76 Million -6.61% 0.28x $51.94 Million

About Biotron Ltd

AU:BIT Australia Biotechnology
Market Cap
$3.94 Million
AU$5.57 Million AUD
Market Cap Rank
#29131 Global
#1608 in Australia
Share Price
AU$0.00
Change (1 day)
+0.00%
52-Week Range
AU$0.00 - AU$0.01
All Time High
AU$0.30
Categories
Companies in Australia Biotechnology
About

Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company's lead antiviral drug is BIT225 that is in Phase 2 clinical trial for the treatment of HIV-1, as well as to treat hepatitis C virus infections; and BIT-HBV001 to treat hepatitis B virus and hepatitis delta virus. It also develops pre… Read more